Trial Profile
Inhaled PPP001 Versus Immediate-release Oral Opioids for the Management of Breakthrough Pain in Cancer Subjects: a Randomized, Open Label, Crossover, Comparison Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary) ; Hydromorphone; Morphine; Oxycodone
- Indications Cancer pain
- Focus Proof of concept; Therapeutic Use
- Acronyms REBORN; REBORN1
- Sponsors Tetra Bio Pharma
- 05 May 2022 According to a Tetra Bio Pharma media release, company has entered into a research and development agreement with Cannvalate for the initiation of this trial in Australia.
- 17 Mar 2022 According to a Tetra Bio Pharma media release, the company received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for QIXLEEF and the FDA provided guidance on the company's nonclinical safety program required to submit a marketing application.
- 29 Nov 2021 Initial Results published in the Tetra Bio Pharma Media Release.